Acta Pharmacologica Sinica 2008 November; 29 (11): 1275-1288; doi: 10.1111/j.1745-7254.2008.00889.x

 
Review
[ Full text]
 
Tumor necrosis factor and cancer, buddies or foes?1
 

Xia WANG2, Yong LIN3,4

2Laboratory of Molecular and Translational Medicine, West China Second University Hospital, Sichuan University, Chengdu 610041, China; 3Molecular Biology and Lung Cancer Program, Lovelace Respiratory Research Institute, Albuquerque, New Mexico 87108, USA

 

Tumor necrosis factor (TNF) is a multifunctional cytokine that plays important roles in diverse cellular events such as cell survival, proliferation, differentiation, and death. As a pro-inflammatory cytokine, TNF is secreted by inflammatory cells, which may be involved in inflammation-associated carcinogenesis. TNF exerts its biological functions through activating distinct signaling pathways such as nuclear factor-κB (NF-κB) and c-Jun N-terminal kinase (JNK). NF-κB is a major cell survival signal that is anti-apoptotic, whereas sustained JNK activation contributes to cell death. The crosstalk between the NF-κB and JNK is involved in determining cellular outcomes in response to TNF. In regard to cancer, TNF is a double-dealer. On one hand, TNF could be an endogenous tumor promoter, because TNF stimulates the growth, proliferation, invasion and metastasis, and tumor angiogenesis of cancer cells. On the other hand, TNF could be a cancer killer. The property of TNF in inducing cancer cell death renders it a potential cancer therapeutic, although much work is needed to reduce its toxicity for systematic TNF administration. Recent studies have focused on sensitizing cancer cells to TNF-induced apoptosis through inhibiting survival signals such as NF-κB, by combined therapy. In this article we provide an overview of the roles of TNF-induced signaling pathways in cancer biology with specific emphasis on carcinogenesis and cancer therapy.

 

Keywords: TNF; apoptosis; NF-κB; carcinogenesis; therapy; therapeutics; signaling pathways

 

1 This study is partly supported by grants from the National Cancer Institute (R03CA125796, to Yong LIN), and National Natural Science Foundation of China (30772539, to Xia WANG).

 

4 Correspondence to Dr Yong LIN, MD, PhD.
Phn 1-505-348-9645.
Fax 1-505-348-4990.
E-mail ylin@lrri.org
Received 2008-06-11     Accepted 2008-07-18

[ Full text]
 

Copyright©APS 2009
Add: 294 Tai-Yuan Road, Shanghai 200031, China
Phn: 86-21-5492-2821  Fax: 86-21-5492-2823
E-mail: aps@mail.shcnc.ac.cn